Program Schedule

1092
Immunogenicity of a 23-valent pneumococcal polysaccharide vaccine in the elderly

Session: Poster Abstract Session: Vaccines: Pneumococcal
Friday, October 10, 2014
Room: The Pennsylvania Convention Center: IDExpo Hall BC
Posters
  • 2014 IDSA poster PDF.pdf (1.3 MB)
  • Background:

    The pneumococcal polysaccharide vaccine (PPSV) was introduced into national immunization program for elderly ( 65 years of age) in Korea on 2013. To evaluate the immune response in this population, anti-pneumococcal antibody titers were studied.

    Methods:

    Sera from 60 pneumococcal vaccine-naïve adults were obtained. They were divided two groups according to their age (65 ~ 75 and ≥ 75). The qualitative antibody response were determined by multiplexed opsonophagocytic killing assay (MOPA) for 14 serotypes (1, 3, 4, 5, 6A, 6B, 6C, 7F, 9V, 14, 18C, 19A, 19F and 23F) before and one month after vaccination.

    Results:

    The geometric mean titers (GMT) for pre- and postimmunization opsonic titers are shown in Figure 1 and Table 1. Reverse cumulative distribution curves are shown in Figure 2. The GMT increased significantly after immunization. The response to the pneumococcal polysaccharide vaccine showed similar responses in both age groups except for serotype 7F and 9V.

    Conclusion:

    PPSV induces a functional immune response for 12 vaccine serotypes as well as 2 vaccine-related serotypes (6A, 6C). PPSV could offer protection against pneumococcal infection in the elderly.

    Table 1. Geometric means for opsonization titers (<75 years old, N=30; 75 years old, N=30)

    Serotypes

    Age

    Preimmunization

    Postimmunization

    GMT

    95%CI

    GMT

    95%CI

    1

    < 75

    10

    6.1-16.6

    162

    83.1-315.9

    75

    8

    5.0-11.2

    94

    46.1-191.9

    3

    < 75

    13

    8.4-19.7

    191

    107.9-339.9

    75

    17

    10.2-28.7

    132

    68.2-255.6

    4

    < 75

    16

    9.9-24.9

    938

    545.1-1,613.9

    75

    34

    16.6-69.5

    1,032

    502.5-2,121.2

    5

    < 75

    18

    12.7-26.7

    207

    128.1-334.9

    75

    23

    14.2-37.0

    225

    131.9-384.7

    6A

    < 75

    64

    28.4-145.9

    1,036

    485.8-2,207.7

    75

    61

    30.8-121.8

    715

    456.5-1,121.1

    6B

    < 75

    280

    130.3-600.1

    3,732

    1,934.0-7,202.3

    75

    309

    138-692

    4,477

    2,591.2-7,735.3

    6C

    < 75

    228

    99.5-523.6

    853

    415.2-1,752.3

    75

    161

    75.9-341.1

    450

    215.3-940.6

    7F

    < 75

    93

    50.4-173.1

    3,443*

    2,279.5-5,201.4

    75

    63

    31.5-127.5

    1,719

    1,094.9-2,700.1

    9V

    < 75

    282*

    157.8-502.6

    1,315*

    792.0-2182.7

    75

    53

    33.7-83.9

    369

    231.3-589.0

    14

    < 75

    317

    160.4-627.3

    3,702

    2091.6-6551.4

    75

    593

    307.6-1,144.1

    3,461

    1,928.1-6,211.4

    18C

    < 75

    103

    53.6-199.5

    2,268

    1,187.5-4330.3

    75

    52

    26.1-104.9

    1,611

    787.2-3,297.7

    19A

    < 75

    273

    149.3-497.4

    4,333

    2,266.4-8,285.2

    75

    477

    220.6-1,030.3

    4,210

    2,432.9-7,286.2

    19F

    < 75

    165

    84.5-322.1

    3,416

    2,098.2-5,561.2

    75

    104

    54.0-202.1

    1,598

    867.0-2,944.3

    23F 

    < 75

    46

    22.7-92.3

    696

    353.3-1372.1

    75

    36

    16.2-78.9

    790

    359.4-1,735.1

    * <75 vs ≥75,  p<0.05

     

    Kyung-Hyo Kim, M.D., Ctr. for Vaccine Evaluation and Study, Ewha Med. Res. Inst., Sch. of Med., Ewha Womans Univ., Seoul, South Korea, Han Wool Kim, M.D., Pediatrics, Sch. of Med., Ewha Womans Univ., Seoul, South Korea and Jong Gyun Ahn, M.D., Sch. of Med., Ewha Womans Univ., Seoul, South Korea

    Disclosures:

    K. H. Kim, None

    H. W. Kim, None

    J. G. Ahn, None

    Findings in the abstracts are embargoed until 12:01 a.m. EDT, Oct. 8th with the exception of research findings presented at the IDWeek press conferences.

    Sponsoring Societies:

    © 2014, idweek.org. All Rights Reserved.

    Follow IDWeek